Huang Jianxiang found that in HCC patients with microvascular invasion, combined camrelizumab therapy based on TACE treatment, VEGF, OPN, and Egfl7 levels were substantially decreased at 1 month and 3 months after surgery compared to before treatment and the degree of reduction was higher than in patients treated with TACE alone, and the quality of life was higher in patients treated with combination therapy. The gene discussed is EGFL7; the disease is hepatocellular carcinoma.